Anebulo Pharmaceuticals ANEB Income Statement (2020-2025)

OTC ANEB
$0.40 -0.02 (-4.76%)
At close: Aug 18, 2026 · 4:00 PM EDT
Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Shares Outstanding (Entity) (Quarter)
12.98M13.61M23.34M23.34M23.34M23.34M25.63M25.63M25.63M25.63M25.63M25.93M25.93M25.93M25.93M27.42M41.08M33.82M41.08M41.08M
Operating items
Research & Development (Quarter)
0.27M1.81M0.72M0.21M0.92M1.12M1.22M1.87M1.09M1.42M1.27M1.06M0.75M0.47M1.31M1.22M0.64M1.13M0.81M1.16M
Selling, General & Administrative (Quarter)
0.28M0.68M0.84M0.86M0.96M1.21M1.39M1.94M1.77M1.08M1.27M1.70M0.92M0.87M1.10M1.37M1.25M1.20M1.45M1.46M
Restructuring Costs (Quarter)
0.02M
Other Operating Expenses (Quarter)
-0.02M
Operating Expenses (Quarter)
0.55M2.48M1.55M1.07M1.88M2.33M2.61M3.81M2.86M2.49M2.54M2.76M1.66M1.34M2.41M2.59M1.89M2.33M2.26M2.62M
Operating Income (Quarter)
-0.55M-2.48M-1.55M-1.07M-1.88M-2.33M-2.61M-3.81M-2.86M-2.49M-2.54M-2.76M-1.66M-1.34M-2.41M-2.59M-1.89M-2.33M-2.26M-2.62M
EBIT (Quarter)
-0.55M-2.48M-1.55M-1.07M-1.88M-2.33M-2.61M-3.81M-2.86M-2.49M-2.54M-2.76M-1.66M-1.34M-2.41M-2.59M-1.89M-2.33M-2.26M-2.62M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.08M6.000.06M0.08M0.07M0.05M0.03M0.01M0.10M0.12M0.11M0.09M
Other Non Operating Income (Quarter)
0.00M-0.00M0.00M-0.00M-212.00-0.02M-0.01M-0.00M0.01M-594.000.00M-124.00-283.0047.00-528.00-431.00-96.00-34.00
Non Operating Income (Quarter)
-0.00M-26.63M0.00M0.00M0.00M-212.00-0.01M0.07M-0.00M0.06M0.04M0.01M-0.01M0.21M0.13M0.22M0.19M0.10M0.62M
Net income details
EBT (Quarter)
-0.56M-2.47M-1.55M-3.47M-5.65M-4.55M-2.97M-3.94M-3.20M-7.18M-3.05M-2.82M-1.95M-1.40M-2.49M-2.68M-2.04M-2.24M-3.63M-2.55M
Profit After Tax (Quarter)
-0.56M-29.11M-1.55M-1.07M-1.88M-2.32M-2.61M-3.83M-2.80M-2.50M-2.48M-2.72M-1.65M-1.35M-2.20M-2.46M-1.68M-2.20M-2.16M-2.00M
Income from Continuing Operations (Quarter)
-0.56M-2.47M-1.55M-3.47M-5.65M-4.55M-2.97M-3.94M-3.20M-7.18M-3.05M-2.82M-1.95M-1.40M-2.49M-2.68M-2.04M-2.24M-3.63M-2.55M
Consolidated Net Income (Quarter)
-0.56M-2.47M-1.55M-3.47M-5.65M-4.55M-2.97M-3.94M-3.20M-7.18M-3.05M-2.82M-1.95M-1.40M-2.49M-2.68M-2.04M-2.24M-3.63M-2.55M
Income towards Parent Company (Quarter)
-0.56M-2.47M-1.55M-3.47M-5.65M-4.55M-2.97M-3.94M-3.20M-7.18M-3.05M-2.82M-1.95M-1.40M-2.49M-2.68M-2.04M-2.24M-3.63M-2.55M
Preferred Dividend Payments (Quarter)
8.21M
Net Income towards Common Stockholders (Quarter)
-8.76M-29.11M-1.55M-3.47M-1.88M-2.32M-2.97M-3.94M-3.20M-7.18M-3.05M-2.82M-1.95M-1.40M-2.49M-2.68M-2.04M-2.24M-3.63M-2.55M
Additional items
EPS (Basic) (Quarter)
-0.68-2.14-0.07-0.15-0.08-0.10-0.13-0.15-0.12-0.29-0.12-0.11-0.08-0.05-0.10-0.10-0.05-0.07-0.09-0.06
EPS (Diluted) (Quarter)
-0.10-0.13-0.15-0.12-0.29-0.12-0.11-0.08-0.05-0.10-0.10-0.05-0.07-0.09-0.06
Shares Outstanding (Quarter)
12.98M13.61M23.34M23.34M23.34M23.34M23.42M25.63M25.63M25.07M25.63M25.79M25.93M25.82M25.93M27.42M41.08M33.82M41.08M41.08M
Shares Outstanding (Diluted) (Quarter)
23.34M23.42M25.63M25.63M25.07M25.63M25.79M25.93M25.82M25.93M27.42M41.08M33.82M41.08M41.08M
EBITDA (Quarter)
-0.55M-2.48M-1.55M-1.07M-1.88M-2.33M-2.61M-3.81M-2.86M-2.49M-2.54M-2.76M-1.66M-1.34M-2.41M-2.59M-1.89M-2.33M-2.26M-2.62M
Interest Expenses (Quarter)
2.04M-0.00M2.64M2.40M3.77M2.23M0.36M0.14M0.42M4.69M0.57M0.14M0.35M0.11M0.10M0.10M0.25M0.04M1.48M0.02M